Eli Lilly
1876
FOUNDED
PUBLIC
STATUS
35K-40K
EMPLOYEES
LLY
STOCK SYMBOL
75
INVESTMENTS
$116.81
SHARE PRICE
(As of Thursday Closing)
Description
Eli Lilly is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta for cancer; Forteo for osteoporosis; Jardiance, Trulicity, Humalog, and Humulin for diabetes; Taltz and Olumiant for immunology; and Cialis for erectile dysfunction.
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NYS
Primary Office
- Lilly Corporate Center
- Indianapolis, IN 46285
- United States
+1 (317) 000-0000
Request full access to PitchBook
You’re viewing a free company profile from the PitchBook Platform. To explore Eli Lilly’s full profile, request a free trial.
Eli Lilly Stock Performance
| 52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
|---|---|---|---|---|---|
| $81.65 - $132.13 | $113B | $117.98 | $6.31 | 15.2M | 971M |
Eli Lilly Financials Summary
|
In Thousands,
USD |
TTM
31-Mar-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
|---|---|---|---|---|
| Enterprise Value | 131,686,312 | 128,273,471 | 97,337,859 | 84,741,092 |
| Revenue | 23,947,900 | 24,555,700 | 22,871,300 | 21,222,100 |
| EBITDA | 4,779,500 | 5,515,500 | 3,822,400 | 4,947,100 |
| Net Income | 6,256,200 | 3,232,000 | (204,100) | 2,737,600 |
| Total Assets | 38,006,800 | 43,908,400 | 44,981,000 | 38,805,900 |
| Total Debt | 15,965,100 | 12,770,900 | 13,647,100 | 10,305,200 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Eli Lilly Valuation and Funding
| Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
|---|
This information is reserved for PitchBook Platform users. To explore Eli Lilly‘s full profile, request access.
Request full access to PitchBookEli Lilly Competitors (23)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Lundbeck | Corporation | Valby, Denmark | 0000 | |||
| 000 000000 00000 | Private Debt Financed | Bresso, Italy | 0000 | 000.00 | 000000000 | 000.00 |
| 0000000 | Formerly VC-backed | Boston, MA | 0000 | 000000000 | ||
| 00000000 000000000 | Failed Transaction (M&A) | West Conshohocken, PA | 00 | 000.00 | 000000&0 | |
| 00000000000 000000 | Private Equity-Backed | Mexico City, Mexico | 000.00 | 0000000000 | 000.00 |
Eli Lilly Investments & Acquisitions (75)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000 0000000000 | 22-Apr-2019 | 000000000 | 00000 | Biotechnology | 000000 00000 |
| 0000 00000000 | 15-Feb-2019 | 000000000000000000 | 000 | Pharmaceuticals | 00000 00000 |
| 00000 00000000000 | 14-Dec-2018 | 000000000000000000 | Drug Discovery | 0000 000000 | |
| 00000000 | 13-Nov-2018 | 00000 00000 00 | 0000 | Biotechnology | 0000 0000000 |
| Dicerna Pharmaceuticals | 29-Oct-2018 | PIPE | 00000 | Pharmaceuticals |
Eli Lilly Exits (24)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 00000000 | 13-Nov-2018 | 00000 00000 00 | 0000 | Completed |
|
| 0000000 | 25-Jul-2018 | 00000 00000 00 | 00000 | Completed |
|
| 0000000 | 19-Dec-2017 | 000000000 | 000 | Completed |
|
| 000000 000000 | 26-Jan-2015 | 000 | 000.00 | Completed |
|
| Zosano Pharma | 19-Aug-2010 | Later Stage VC | 00.00 | Completed |
|
Eli Lilly Subsidiaries (8)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| ARMO BioSciences | Biotechnology | Redwood City, CA | 2012 |
| 0000000 000000000 | Biotechnology | Montreal, Canada | 0000 |
| 0000000 0000000000 | Pharmaceuticals | Cambridge, MA | 0000 |
| 00000 0000 0000000 | Venture Capital | Shanghai, China | 0000 |
| 00000 00000000 | Corporate Venture Capital | Indianapolis, IN | 0000 |
Eli Lilly Investors
| Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
|---|
This information is reserved for PitchBook Platform users. To explore Eli Lilly‘s full profile, request access.
Request full access to PitchBookEli Lilly Executive Team (60)
23 Former Executives
You’re viewing 5 of 60 executives. Get the full list »Eli Lilly Board Members (7)
| Name | Representing | Role | Since | Contact Info |
|---|---|---|---|---|
| 00000 00000 | Eli Lilly | Chairman & Chief Executive Officer | 000 0000 | |
| 00000 000000 | Self | Chairman, Directors and Corporate Governance Committee | 000 0000 | |
| 0000 0000000 | Self | Chairman, Finance Committee | 000 0000 | |
| 00000 000000 | Self | Board Member | 000 0000 | |
| 00000 0000000 | Self | Board Member | 000 0000 |
2 Former Board Members
You’re viewing 5 of 7 board members. Get the full list »